N/A
N=216
Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Nasal Carriers of Staphylococcus Aureus
Bottom Line
View on ClinicalTrials.gov: NCT00997139 ↗Enrolled (actual)
216
Serious AEs
0.0%
Results posted
May 2012
Primary outcome: Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Nov 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Carrier Rate for Staphylococcus Aureus |
20.8 | — |
| PRIMARY MSSA Clearance Rate |
57.1 | — |
| PRIMARY MRSA Clearance Rate |
— | — |
Summary
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.
Eligibility Criteria
Inclusion Criteria
- Willing and able to give informed consent
- Must have consented prior to registration for the study
Exclusion Criteria
- active infection
- concurrent treatment with antibiotics, topical or systemic
- S. aureus decolonization attempt in prior six months
- history of HIV
- chemotherapy or systemic immunosuppressive therapy
- history of neomycin allergy or sensitivity
Data sourced from ClinicalTrials.gov (NCT00997139). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.